A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06077760
Trial Phases:	Phase III	Protocol IDs:	V940-002 (primary) NCI-2023-09110 2023-504923-20 2023-504923-20-00 jRCT2061240063 PHRR240705-007252 U1111-1290-3969
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06077760

Summary

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus
placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely
resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer
(NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is
superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as
assessed by the investigator.

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.